secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K/A
Filed at:   2021-10-05T23:59:59+00:00
Accession:  0001104659-21-123200
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma amends 8-K to disclose consulting agreement with departing EVP & General Counsel
--------------------------------------------------------------------------------

- Bradford Shafer, EVP & General Counsel, resigned effective Sep 30, 2021; consulting agreement signed same day.
- Consulting term runs Sep 30 to Nov 30, 2021; up to 5 hours/week for transition support.
- Restricted share units originally vesting Nov 20, 2021 and Feb 20, 2022 will both vest on Nov 20, 2021.
- Agreement includes standard confidentiality, non-solicitation (12 months), and invention assignment provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465921123200/0001104659-21-123200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465921123200/tm2129216d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-123200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer